Navigating Dupixent Prior Authorizations with Cohere Health
Successfully managing prior authorizations for high-volume specialty drugs like Dupixent when processed by Cohere Health requires a precise understanding of payer-specific clinical criteria and submission pathways. Klivira automates this complex interaction.
For revenue cycle directors and prior authorization coordinators, navigating the specific requirements for Dupixent (dupilumab) through Cohere Health's AI-driven platform presents unique challenges. This includes understanding the nuances of pharmacy versus medical benefit, ePA submission protocols, and the detailed clinical documentation necessary for approval. Optimizing this workflow is critical for patient access and revenue integrity.
Dupixent PA Workflow through Cohere Health: Pharmacy vs. Medical Benefit
Dupixent, an IL-4/IL-13 inhibitor, is predominantly managed under the pharmacy benefit due to its self-administered subcutaneous injection route. This means prior authorization requests are typically submitted via electronic prior authorization (ePA) using the NCPDP SCRIPT standard. Cohere Health, as a payer-side platform, processes these ePA submissions, applying payer-specific clinical criteria to determine approval for indications such as atopic dermatitis, asthma, eosinophilic esophagitis, and chronic rhinosinusitis with nasal polyps.
Addressing Formulary and Step-Therapy Requirements
Cohere Health's platform evaluates Dupixent PA requests against the payer's formulary, which often includes step-therapy protocols. For instance, approval for atopic dermatitis may require documented failure or contraindication to topical corticosteroids. Similarly, for asthma, evidence of inadequate control on inhaled corticosteroids or other controller medications is frequently mandated. Klivira’s integration streamlines the submission of this crucial clinical history, ensuring all prerequisite information is presented accurately to Cohere Unify.
Key Documentation for Dupixent Cohere Health PAs
- Diagnosis confirmation and severity assessment (e.g., EASI, SCORAD for atopic dermatitis; FEV1 for asthma; eosinophil count for EoE/CRSwNP).
- Detailed history of prior treatment failures or intolerances, including dates and duration of trials.
- Clinical notes supporting the current indication and patient's response to previous therapies.
- Relevant lab results (e.g., IgE levels, eosinophil counts) if required by payer criteria.
- Prescriber attestation of medical necessity and adherence to evidence-based guidelines.
Optimizing ePA Submissions for IL-4/IL-13 Inhibitors
Effective ePA submission for IL-4/IL-13 inhibitors like Dupixent requires meticulous data capture and transmission. Klivira’s platform automates the extraction of necessary clinical data from the EMR, populating the ePA request form (NCPDP SCRIPT) with precision. This reduces manual data entry errors and accelerates the submission process to Cohere Health, facilitating quicker review and determination.
Klivira's Role in Expediting Cohere Health Approvals
Klivira integrates directly with your EMR and payer portals, including those utilizing Cohere Health, to automate the Dupixent prior authorization process. By standardizing data submission and proactively identifying missing clinical information, Klivira helps clinics and health systems meet Cohere's specific requirements, reducing manual work and improving approval rates for specialty medications.
Frequently asked questions
What is the primary benefit type for Dupixent PA requests processed by Cohere Health?
Dupixent PA requests processed by Cohere Health are primarily managed under the pharmacy benefit due to its self-administered subcutaneous injection. This means submissions will generally follow the ePA (NCPDP SCRIPT) pathway.
What common step-therapy requirements does Cohere Health enforce for Dupixent?
Common step-therapy requirements for Dupixent via Cohere Health often include documented failure or contraindication to less intensive therapies. For atopic dermatitis, this typically involves prior topical corticosteroid trials. For asthma, evidence of inadequate control on inhaled corticosteroids is usually required.
How does Klivira assist with Dupixent PA submissions to Cohere Health?
Klivira automates the extraction of relevant clinical data from your EMR, populating and submitting ePA requests for Dupixent directly to Cohere Health. This ensures all required documentation, including step-therapy failures and diagnostic criteria, is accurately and efficiently transmitted, reducing manual effort and potential delays.
Are there specific diagnostic criteria Cohere Health looks for in Dupixent PAs?
Yes, Cohere Health evaluates Dupixent PAs against payer-specific clinical criteria which often include specific diagnostic codes and severity assessments. For instance, for atopic dermatitis, scores like EASI or SCORAD may be required, while for asthma, FEV1 measurements or eosinophil counts might be critical.
Can Klivira handle multiple Dupixent indications for Cohere Health PAs?
Yes, Klivira is designed to manage prior authorizations for all approved Dupixent indications, including atopic dermatitis, asthma, eosinophilic esophagitis, and chronic rhinosinusitis with nasal polyps. Our platform ensures that indication-specific documentation is correctly submitted to Cohere Health.
Related coverage
Ready to automate this workflow?
See how Klivira automates prior authorizations for your team.
Request a demo